Search research articles
Contact Us
Filters
Showing results (41-50 of 108) with videos related to
Page
of 11
Sort By:
Bone Marrow Transplantation
|
November 16, 2004
Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients
M Krejci, T Buchler, R Hajek, et al.
Neoplasma
|
May 29, 2008
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
M Zemanova, V Scudla, Z Adam, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
August 14, 2014
Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient
S Sevčíková, L Kubiczková, L Sedlaříková, et al.
Neoplasma
|
February 27, 2007
Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients
M Krejci, R Hajek, T Buchler, et al.
Vnitrni Lekarstvi
|
October 1, 2013
[Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature]
Z Adam, A Pejchalová, G Chlupová, et al.
Neoplasma
|
September 8, 2007
Dendritic cell counts and their subsets during treatment of multiple myeloma
L Kovarova, T Buchler, L Pour, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 15, 2017
Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies
L Brozova, J Jarkovský, L Pour, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 2, 2019
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
M Campioni, I Agirrezabal, R Hajek, et al.
Vnitrni Lekarstvi
|
April 17, 2010
[More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)]
Z Adam, M Nedbálková, M Krejcí, et al.
Neoplasma
|
October 24, 2007
Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance
Z Adam, K Bolcak, J Stanicek, et al.
Page
of 11
Search research articles
Search
Showing results (41-50 of 108) with videos related to
Sort By:
Page
of 11
Bone Marrow Transplantation
|
November 16, 2004
Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients
M Krejci, T Buchler, R Hajek, et al.
Neoplasma
|
May 29, 2008
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma
M Zemanova, V Scudla, Z Adam, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
August 14, 2014
Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient
S Sevčíková, L Kubiczková, L Sedlaříková, et al.
Neoplasma
|
February 27, 2007
Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients
M Krejci, R Hajek, T Buchler, et al.
Vnitrni Lekarstvi
|
October 1, 2013
[Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature]
Z Adam, A Pejchalová, G Chlupová, et al.
Neoplasma
|
September 8, 2007
Dendritic cell counts and their subsets during treatment of multiple myeloma
L Kovarova, T Buchler, L Pour, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti
|
September 15, 2017
Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies
L Brozova, J Jarkovský, L Pour, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 2, 2019
Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data
M Campioni, I Agirrezabal, R Hajek, et al.
Vnitrni Lekarstvi
|
April 17, 2010
[More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)]
Z Adam, M Nedbálková, M Krejcí, et al.
Neoplasma
|
October 24, 2007
Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance
Z Adam, K Bolcak, J Stanicek, et al.
Page
of 11